Author: Piers Townley
-
Wearing an electronic cap to improve glioblastoma survival
Patients with glioblastoma are wearing a cap that delivers electronic fields to treat their brain tumours
-
Society for Neuro-Oncology annual meeting (part two)
Our Head of Research, Phil Hexley, outlines what happened at SNO: the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology
-
Developing a Vaccine to Treat Diffuse Midline Glioma
Researchers at UC San Francisco develop a vaccine to treat diffuse midline glioma by using the patient’s immune system to attack the tumour cells
-
Society for Neuro-Oncology annual meeting (part one)
Our Head of Research, Phil Hexley, outlines what happened at SNO: the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology
-
Our meeting with the Less Survivable Cancers Taskforce
Yesterday, along with partners of the Less Survivable Cancers Taskforce, we met with Government Minister Steve Brine, Parliamentary Under-Secretary (Department of Health)
-
Kings College Hospital appoints our first Clinical Nurse Specialist
The Neuro-Oncology team at King’s College Hospital are excited to welcome Charlotte Robinson into the first low grade glioma CNS post in the UK
-
Brain cancer drug, PAC-1 is approved for Phase 1(b) Clinical Trials
PAC-1, an anti-cancer drug is approved for phase 1(b) clinical trials in humans by the US Food and Drug Administration
-
MSPs call for action in debate on brain tumours
On Thursday Alexander Stewart MSP led a debate in the Scottish Parliament on Brain Tumour Awareness in Scotland, as several MSPs expressed their support for action to raise greater awareness of the disease
-
The implications of the Scottish Parliament brain tumour debate
Our Policy & Public Affairs Manager Cameron Miller, outlines tomorrow’s MSP debate in the Scottish Parliament
-
Launching our 2017 Christmas Appeal
In the UK, 11,000 people are diagnosed with a brain tumour every year. This figure simply has to change
-
HeadSmart “a model” for awareness campaigns in low-survival cancers
The multi-award winning HeadSmart campaign has gained international recognition after being recommended to the Australian Government as a “model to inform the public about low survival rate cancers and their symptoms”
-
Post APPG Brexit
This week our Chief Scientific Officer, Dr David Jenkinson, is speaking at a meeting of the All Party Parliamentary Group on brain tumours about what risks Brexit poses
-
New gene therapy could have potential to treat recurrent glioblastomas
Researchers in collaboration with ZIOPHARM Oncology, a biopharmaceutical company announce positive updates on a Phase 1 clinical trials testing a new therapy
-
MSPs to debate need for greater awareness of brain tumours in Scottish Parliament
Inspired by our Community Fundraiser Shona Richardson’s personal story, Alexander Stewart MSP has tabled a debate in the Scottish Parliament on 7 December
-
Launching our Employment Resources for patients
The resources have been developed in response to a nationwide gap in information. They will improve the quality of life for those affected
-
Brain tumours: The hot soap storyline
Are they good for raising awareness or should the bubble burst? Our senior media & PR Officer Carol Dyce examines
-
Meet the researcher: Ally Rooney
Ally is an academic psychiatry trainee, nearly a Consultant psychiatrist, currently funded by The Charity to study non-drug treatments for fatigue in people living with a brain tumour
-
Rugby legend Lewis Moody heads up the headwest Costa Rica coast-to-coast challenge
Lewis and his team headwest to raise £75,000 to help fund HeadSmart
-
Ovarian cancer drug olaparib has the potential to treat glioblastoma
Researchers at Glasgow University have discovered that ovarian cancer drug, olaparib, has the potential to treat patients with glioblastomas
-
New glioblastoma and anaplastic astrocytoma book
Gideon Burrows has written his second book with personal stories, experiences, statistics and information, helped by a huge amount of people directly affected
-
Gene therapy to treat recurrent high-grade gliomas gets accelerated to Phase 3 clinical trials
A gene therapy to treat recurrent high-grade gliomas is accelerated to Phase 3 clinical trials, after the success of Phase 1 clinical trials by the US Food and Drug Administration (FDA)
-
The uniting of our international brain tumour community
Our Policy & Public Affairs Manager, Cameron Miller, on Australia’s Cure Brain Cancer AU$100m investment fund
-
A potential combination treatment targeting glioblastoma
A team of researchers at UCLA have discovered a combination of drugs to prevent the growth of glioblastomas, as well as kill tumour cells in mice with glioblastomas
-
The hurdles of medical research that face the SNP
Jonathan Canty, our Project Information Analyst, reflects on the SNP Conference in Glasgow last week